Akcea Therapeutics

General Information

We are a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Our goal is to become the premier company offering treatments for inadequately treated lipid disorders. We are advancing a mature pipeline of four novel drugs with the potential to treat multiple diseases. Our drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc., or Ionis.

Employees: 30
Founded: 2014
Contact Information
Address 55 Cambridge Parkway, Suite 100, Cambridge, MA 02142, US
Phone Number (617) 207-0202
Web Address http://www.akceatx.com
View Prospectus: Akcea Therapeutics
Financial Information
Market Cap $513.6mil
Revenues $0 mil (last 12 months)
Net Income $-127.6 mil (last 12 months)
IPO Profile
Symbol AKCA
Exchange NASDAQ
Shares (millions): 15.6
Price range $8.00 - $8.00
Est. $ Volume $125.0 mil
Manager / Joint Managers Cowen and Company/ Stifel/ Wells Fargo Securities
CO-Managers BMO Capital Markets
Expected To Trade: 7/14/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change